Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels

Cem Akin, Darya Soto, Erica Brittain, Adhuna Chhabra, Lawrence B. Schwartz, George H. Caughey, Dean D. Metcalfe

Research output: Contribution to journalArticle

Abstract

Serum mast cell tryptase levels are used as a diagnostic criterion and surrogate marker of disease severity in mastocytosis. Approximately 29% of the healthy population lacks α tryptase genes; however, it is not known whether lack of α tryptase genes leads to variability in tryptase levels or impacts on disease severity in mastocytosis. We have thus analyzed tryptase haplotype in patients with mastocytosis, computing correlations between haplotype and plasma total and mature tryptase levels; and disease category. We found: (1) the distribution of tryptase haplotype in patients with mastocytosis appeared consistent with Hardy-Weinberg equilibrium and the distribution in the general population; (2) the disease severity and plasma tryptase levels were not affected by the number of α or β tryptase alleles in this study; and (3) information about the tryptase haplotype did not provide any prognostic value about the severity of disease. Total and mature tryptase levels positively correlated with disease severity, as well as prothrombin time and partial thromboplastin time, and negatively correlated with the hemoglobin concentration.

Original languageEnglish (US)
Pages (from-to)268-271
Number of pages4
JournalClinical Immunology
Volume123
Issue number3
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Mastocytosis
Tryptases
Haplotypes
Partial Thromboplastin Time
Prothrombin Time
Population
Genes
Hemoglobins
Biomarkers

Keywords

  • Allele
  • Genotype
  • Haplotype
  • Mastocytosis
  • Partial thromboplastin time
  • Prothrombin time
  • Tryptase

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Akin, C., Soto, D., Brittain, E., Chhabra, A., Schwartz, L. B., Caughey, G. H., & Metcalfe, D. D. (2007). Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels. Clinical Immunology, 123(3), 268-271. https://doi.org/10.1016/j.clim.2007.02.007

Tryptase haplotype in mastocytosis : Relationship to disease variant and diagnostic utility of total tryptase levels. / Akin, Cem; Soto, Darya; Brittain, Erica; Chhabra, Adhuna; Schwartz, Lawrence B.; Caughey, George H.; Metcalfe, Dean D.

In: Clinical Immunology, Vol. 123, No. 3, 06.2007, p. 268-271.

Research output: Contribution to journalArticle

Akin, C, Soto, D, Brittain, E, Chhabra, A, Schwartz, LB, Caughey, GH & Metcalfe, DD 2007, 'Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels', Clinical Immunology, vol. 123, no. 3, pp. 268-271. https://doi.org/10.1016/j.clim.2007.02.007
Akin, Cem ; Soto, Darya ; Brittain, Erica ; Chhabra, Adhuna ; Schwartz, Lawrence B. ; Caughey, George H. ; Metcalfe, Dean D. / Tryptase haplotype in mastocytosis : Relationship to disease variant and diagnostic utility of total tryptase levels. In: Clinical Immunology. 2007 ; Vol. 123, No. 3. pp. 268-271.
@article{a1f22fb8abc747529a46e392b338c48d,
title = "Tryptase haplotype in mastocytosis: Relationship to disease variant and diagnostic utility of total tryptase levels",
abstract = "Serum mast cell tryptase levels are used as a diagnostic criterion and surrogate marker of disease severity in mastocytosis. Approximately 29{\%} of the healthy population lacks α tryptase genes; however, it is not known whether lack of α tryptase genes leads to variability in tryptase levels or impacts on disease severity in mastocytosis. We have thus analyzed tryptase haplotype in patients with mastocytosis, computing correlations between haplotype and plasma total and mature tryptase levels; and disease category. We found: (1) the distribution of tryptase haplotype in patients with mastocytosis appeared consistent with Hardy-Weinberg equilibrium and the distribution in the general population; (2) the disease severity and plasma tryptase levels were not affected by the number of α or β tryptase alleles in this study; and (3) information about the tryptase haplotype did not provide any prognostic value about the severity of disease. Total and mature tryptase levels positively correlated with disease severity, as well as prothrombin time and partial thromboplastin time, and negatively correlated with the hemoglobin concentration.",
keywords = "Allele, Genotype, Haplotype, Mastocytosis, Partial thromboplastin time, Prothrombin time, Tryptase",
author = "Cem Akin and Darya Soto and Erica Brittain and Adhuna Chhabra and Schwartz, {Lawrence B.} and Caughey, {George H.} and Metcalfe, {Dean D.}",
year = "2007",
month = "6",
doi = "10.1016/j.clim.2007.02.007",
language = "English (US)",
volume = "123",
pages = "268--271",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Tryptase haplotype in mastocytosis

T2 - Relationship to disease variant and diagnostic utility of total tryptase levels

AU - Akin, Cem

AU - Soto, Darya

AU - Brittain, Erica

AU - Chhabra, Adhuna

AU - Schwartz, Lawrence B.

AU - Caughey, George H.

AU - Metcalfe, Dean D.

PY - 2007/6

Y1 - 2007/6

N2 - Serum mast cell tryptase levels are used as a diagnostic criterion and surrogate marker of disease severity in mastocytosis. Approximately 29% of the healthy population lacks α tryptase genes; however, it is not known whether lack of α tryptase genes leads to variability in tryptase levels or impacts on disease severity in mastocytosis. We have thus analyzed tryptase haplotype in patients with mastocytosis, computing correlations between haplotype and plasma total and mature tryptase levels; and disease category. We found: (1) the distribution of tryptase haplotype in patients with mastocytosis appeared consistent with Hardy-Weinberg equilibrium and the distribution in the general population; (2) the disease severity and plasma tryptase levels were not affected by the number of α or β tryptase alleles in this study; and (3) information about the tryptase haplotype did not provide any prognostic value about the severity of disease. Total and mature tryptase levels positively correlated with disease severity, as well as prothrombin time and partial thromboplastin time, and negatively correlated with the hemoglobin concentration.

AB - Serum mast cell tryptase levels are used as a diagnostic criterion and surrogate marker of disease severity in mastocytosis. Approximately 29% of the healthy population lacks α tryptase genes; however, it is not known whether lack of α tryptase genes leads to variability in tryptase levels or impacts on disease severity in mastocytosis. We have thus analyzed tryptase haplotype in patients with mastocytosis, computing correlations between haplotype and plasma total and mature tryptase levels; and disease category. We found: (1) the distribution of tryptase haplotype in patients with mastocytosis appeared consistent with Hardy-Weinberg equilibrium and the distribution in the general population; (2) the disease severity and plasma tryptase levels were not affected by the number of α or β tryptase alleles in this study; and (3) information about the tryptase haplotype did not provide any prognostic value about the severity of disease. Total and mature tryptase levels positively correlated with disease severity, as well as prothrombin time and partial thromboplastin time, and negatively correlated with the hemoglobin concentration.

KW - Allele

KW - Genotype

KW - Haplotype

KW - Mastocytosis

KW - Partial thromboplastin time

KW - Prothrombin time

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=34249285859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249285859&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2007.02.007

DO - 10.1016/j.clim.2007.02.007

M3 - Article

C2 - 17449330

AN - SCOPUS:34249285859

VL - 123

SP - 268

EP - 271

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -